We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More
Read MoreHide Full Article
Per the Earnings Trends report as of Aug 5, 79.6% of the companies in the Medical sector, constituting nearly 84.3% of the sector’s market capitalization, have already reported earnings. While 86% beat earnings estimates, 79.1% beat the same for sales. Earnings are up 4.4% year over year while revenues are up 4%. Overall, second-quarter earnings for the Medical sector, comprising pharma/biotech and medical device companies, are expected to rise 1.9% on 3.4% sales increase.
It has been a mixed second-quarter earnings season for the drug/biotech stocks so far. Most companies beat estimates for earnings while missing the same for sales. However, AstraZeneca, Regeneron, Bristol-Myers, Vertex Pharmaceuticals and AbbVie beat estimates on both counts. As expected, almost all companies witnessed a significant negative impact on their top line due to business disruption and reduced doctor visits in the United States amid COVID-19-related mobility restrictions & limitations. Meanwhile, coronavirus-related stockpiling benefits, which increased sales of several medicines in the first quarter, reversed in the second quarter and hurt sales. Lower selling, general and administrative costs due to COVID-19 related restrictions on travel and promotional activities gave a boost to earnings.
Let’s analyze five drug/biotech companies that are set to report second-quarter 2020 results on Aug 10.
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 or #3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for earnings stands at a loss of 37 cents per share.
Investors will be keen to know about the progress of Novavax’s coronavirus vaccine candidate, NVX-CoV2373 when the company reports results.
Intercept Pharmaceuticals
This New York-based biotech has an Earnings ESP of +10.76% and a Zacks Rank of 3, indicating a likely positive surprise. The Zacks Consensus Estimate for the second quarter is pegged at a loss of $2.88 per share.
In the trailing four quarters, Intercept beat estimates in two quarters and missed in the other two with the average negative earnings surprise being 3.78%.
Intercept Pharmaceuticals, Inc. Price and EPS Surprise
The biotech’s earnings beat the Zacks Consensus Estimate in two of the last four quarters while missing in the other two with the average earnings surprise being 12.83%.
Reata Pharmaceuticals, Inc. Price and EPS Surprise
The company’s earnings beat estimates only once in the last four quarters while missing in the other three, resulting in four-quarter average negative earnings surprise of 83.46%.
Halozyme Therapeutics, Inc. Price and EPS Surprise
In the trailing four quarters, the company delivered an earnings beat once, missed estimates in two quarters and posted in-line results in another. The four-quarter negative earnings surprise is 8.66%, on average
Amicus has an Earnings ESP of -5.19% and a Zacks Rank #5.
The Zacks Consensus Estimate stands at a loss of 26 cents per share
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
Image: Shutterstock
Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More
Per the Earnings Trends report as of Aug 5, 79.6% of the companies in the Medical sector, constituting nearly 84.3% of the sector’s market capitalization, have already reported earnings. While 86% beat earnings estimates, 79.1% beat the same for sales. Earnings are up 4.4% year over year while revenues are up 4%. Overall, second-quarter earnings for the Medical sector, comprising pharma/biotech and medical device companies, are expected to rise 1.9% on 3.4% sales increase.
It has been a mixed second-quarter earnings season for the drug/biotech stocks so far. Most companies beat estimates for earnings while missing the same for sales. However, AstraZeneca, Regeneron, Bristol-Myers, Vertex Pharmaceuticals and AbbVie beat estimates on both counts. As expected, almost all companies witnessed a significant negative impact on their top line due to business disruption and reduced doctor visits in the United States amid COVID-19-related mobility restrictions & limitations. Meanwhile, coronavirus-related stockpiling benefits, which increased sales of several medicines in the first quarter, reversed in the second quarter and hurt sales. Lower selling, general and administrative costs due to COVID-19 related restrictions on travel and promotional activities gave a boost to earnings.
Let’s analyze five drug/biotech companies that are set to report second-quarter 2020 results on Aug 10.
Novavax (NVAX - Free Report)
Novavax missed earnings estimates thrice in the last four quarter while beating in one with the average surprise being 0.71%.
Novavax, Inc. Price and EPS Surprise
Novavax, Inc. price-eps-surprise | Novavax, Inc. Quote
Novavax has an Earnings ESP of 0.00% and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Per our proven model, stocks with the combination of a positive Earnings ESP and a Zacks Rank #1, #2 or #3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
The Zacks Consensus Estimate for earnings stands at a loss of 37 cents per share.
Investors will be keen to know about the progress of Novavax’s coronavirus vaccine candidate, NVX-CoV2373 when the company reports results.
Intercept Pharmaceuticals
This New York-based biotech has an Earnings ESP of +10.76% and a Zacks Rank of 3, indicating a likely positive surprise. The Zacks Consensus Estimate for the second quarter is pegged at a loss of $2.88 per share.
In the trailing four quarters, Intercept beat estimates in two quarters and missed in the other two with the average negative earnings surprise being 3.78%.
Intercept Pharmaceuticals, Inc. Price and EPS Surprise
Intercept Pharmaceuticals, Inc. price-eps-surprise | Intercept Pharmaceuticals, Inc. Quote
Reata Pharmaceuticals
The biotech’s earnings beat the Zacks Consensus Estimate in two of the last four quarters while missing in the other two with the average earnings surprise being 12.83%.
Reata Pharmaceuticals, Inc. Price and EPS Surprise
Reata Pharmaceuticals, Inc. price-eps-surprise | Reata Pharmaceuticals, Inc. Quote
This Zacks Rank #4 (Sell) company has an Earnings ESP of 0.00%. The Zacks Consensus Estimate stands at a loss of $2.22 per share.
Halozyme Therapeutics (HALO - Free Report)
The company’s earnings beat estimates only once in the last four quarters while missing in the other three, resulting in four-quarter average negative earnings surprise of 83.46%.
Halozyme Therapeutics, Inc. Price and EPS Surprise
Halozyme Therapeutics, Inc. price-eps-surprise | Halozyme Therapeutics, Inc. Quote
Halozyme has an Earnings ESP of 0.00% and a Zacks Rank #2.
The Zacks Consensus Estimate for earnings stands at 25 cents per share.
Amicus Therapeutic (FOLD - Free Report)
In the trailing four quarters, the company delivered an earnings beat once, missed estimates in two quarters and posted in-line results in another. The four-quarter negative earnings surprise is 8.66%, on average
Amicus has an Earnings ESP of -5.19% and a Zacks Rank #5.
The Zacks Consensus Estimate stands at a loss of 26 cents per share
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.3% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>